Travoprost - Generic Drug Details

What are the generic sources for travoprost and what is the scope of freedom to operate?

Travoprost is the generic ingredient in five branded drugs marketed by Glaukos, Novartis, Alcon Pharms Ltd, Sandoz, Alembic, Apotex, Chartwell Rx, Gland, Lupin Ltd, Micro Labs, Mylan, and Somerset Theraps Llc, and is included in thirteen NDAs. There are eleven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Travoprost has one hundred and thirty-nine patent family members in twenty-five countries.

There are fifteen drug master file entries for travoprost. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for travoprost

International Patents:	139
US Patents:	11
Tradenames:	5
Applicants:	12
NDAs:	13
Drug Master File Entries:	15
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	107
Patent Applications:	7,692
Drug Prices:	Drug price trends for travoprost
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for travoprost
What excipients (inactive ingredients) are in travoprost?	travoprost excipients list
DailyMed Link:	travoprost at DailyMed

See drug prices for travoprost

See drug sales revenues for travoprost

Recent Clinical Trials for travoprost

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Salus University	Phase 4
Glaukos Corporation	PHASE2
Assiut University	Phase 4

See all travoprost clinical trials

Generic filers with tentative approvals for TRAVOPROST

Applicant	Application No.	Strength	Dosage Form
		0.004%	SOLUTION; OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for travoprost

Drug Class

Prostaglandin Analog

Medical Subject Heading (MeSH) Categories for travoprost

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for travoprost

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for TRAVOPROST

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IZBA	Ophthalmic Solution	travoprost	0.003%	204822	1	2015-12-30
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19
TRAVATAN	Ophthalmic Solution	travoprost	0.004%	021257	1	2008-11-28

US Patents and Regulatory Information for travoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	205050-001	Jul 7, 2017	AT2	RX	No	No
Chartwell Rx	TRAVOPROST	travoprost	SOLUTION/DROPS;OPHTHALMIC	091340-001	Mar 1, 2013		RX	No	Yes
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y
Glaukos	IDOSE TR	travoprost	IMPLANT;INTRACAMERAL	218010-001	Dec 13, 2023		RX	Yes	Yes			Y	Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes			Y
Novartis	IZBA	travoprost	SOLUTION/DROPS;OPHTHALMIC	204822-001	May 15, 2014		DISCN	Yes	No			Y

Expired US Patents for travoprost

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006
Alcon Pharms Ltd	TRAVATAN	travoprost	SOLUTION/DROPS;OPHTHALMIC	021257-001	Mar 16, 2001

EU/EMA Drug Approvals for travoprost

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for travoprost

Country	Patent Number	Title	Estimated Expiration
China	101516332
European Patent Office	3603590
Australia	2025283494
Japan	4785970
Japan	2017047262
European Patent Office	2265251

Supplementary Protection Certificates for travoprost

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	PA2012017,C1920764	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
1920764	2012/033	Ireland		PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
1920764	PA2012017	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1920764	1290027-0	Sweden		PRODUCT NAME: TRAVOPROST

Market Dynamics and Financial Trajectory for Travoprost

Last updated: February 19, 2026

Travoprost, a prostaglandin analog used to treat glaucoma and ocular hypertension, shows steady clinical adoption driven by its efficacy and safety profile. Its market growth aligns with increasing prevalence of glaucoma globally. The drug's financial trajectory suggests moderate revenue stability with potential growth from new formulations and expanded indications.

Market Size and Growth Drivers

Global Glaucoma Market Overview

The global glaucoma treatment market was valued at approximately USD 5.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030, reaching an estimated USD 8.7 billion by 2030 (Grand View Research, 2022). The growth is driven by an aging population, improved diagnostic methods, and rising awareness of ocular health.

Travoprost Market Share

Travoprost accounts for an estimated 12-15% of the glaucoma medication market share in developed regions. Its primary competitors include latanoprost, bimatoprost, and tafluprost. The drug's advantages over competitors are its comparable efficacy and potentially lower intraocular pressure (IOP) fluctuations.

Regional Market Penetration

North America dominates with a share exceeding 45%, attributable to high prevalence, advanced healthcare infrastructure, and patent protections. Europe holds roughly 25%, while Asia-Pacific, experiencing fast growth, accounts for about 20% of the market. Emerging markets in Latin America and Africa lag, but show increasing adoption.

Product Pipeline and Innovation

Formulation Developments

Recent innovations include preservative-free formulations and combination therapies, which improve patient compliance. Notably, the introduction of fixed-dose combinations with other ocular hypotensives aims to expand market size by targeting patients with more severe glaucoma or requiring multi-drug regimens.

Patent and Exclusivity

As of 2023, travoprost’s primary patent protections extended into 2026, with some formulations having earlier expiry dates. Patent expirations typically lead to increased competition from generics, which can impact revenue trajectories.

Revenue and Financial Outlook

Historical Revenue Data

Major pharmaceutical companies producing travoprost (e.g., Allergan, Santen) report annual global sales in the range of USD 200-300 million for branded formulations. For instance, Allergan's optic products indicated USD 250 million in 2022 (company annual report).

Projected Revenue Trends

Post-patent expiry, generic competition is expected to reduce branded revenues by up to 70%. However, continued growth in the glaucoma market and expanded indications could mitigate declines through volume increases. Sales of preservative-free and combination formulations are expected to boost growth by around 6-8% annually in the next five years.

Impact of Market Entry Strategies

Companies employing aggressive marketing, strong distribution networks, and investments in patient adherence programs can sustain or increase revenue despite generic competition. Increased adoption in developing countries further enhances revenue prospects.

Competitive Landscape

Company	Product Name	Market Share	Key Strategies	Patent Status
Allergan (AbbVie)	Travatan Z	High	Brand loyalty, global distribution	Patent until 2026
Santen	Vyzulta (combination)	Moderate	Formulation innovation	Patent until 2024
Others	Generic versions	Growing	Price competition, expanded access	Patent expired or pending

Genuine market growth depends on innovation, patent protections, and regulatory pathways for new formulations.

Regulatory Environment

Approvals and Reimbursements

Regulatory approvals for travoprost are well-established in the US, EU, and Japan. Reimbursements policies favor preserved and preservative-free formulations. Changes in healthcare reimbursement schemes can influence sales volumes.

Patent Litigation and Conflicts

Patent disputes from generic manufacturers can delay or limit the entry of biosimilars, shaping revenue trajectories. Patent litigation in key markets remains active through 2025, influencing market stability.

Risks and Challenges

• Patent expiry leading to price erosion.
• Competition from alternative therapies like laser surgery and newer drugs.
• Regulatory delays for new formulations.
• Limited awareness and access in emerging markets.

Summary and Future Outlook

Travoprost will experience modest growth within the broader glaucoma market, driven by formulations innovation and expanded geographic reach. Emerging markets pose growth opportunities, but patent expirations and competition from generics stand as key risks. Market strategies focused on product differentiation and patient adherence will influence revenue trajectories.

---

Key Takeaways

• The global glaucoma market is expected to reach USD 8.7 billion by 2030, with travoprost holding a significant share.
• Revenue from branded travoprost has stabilized around USD 200-300 million annually and may decline post-patent expiry unless offset by formulation and market expansion.
• Patent protections extend until 2026, after which generic competition will intensify.
• Innovation in preservative-free and combination formulations supports growth.
• Regional dynamics heavily influence revenue, with North America leading, followed by Europe and Asia-Pacific.

---

FAQs

1. When does the main patent for travoprost expire?
In 2026, after which generic versions are expected to enter key markets.

2. What factors influence the adoption of travoprost in emerging markets?
Pricing, regulatory approval, healthcare infrastructure, and local disease prevalence.

3. How do new formulations impact the market?
They improve patient compliance, extend patent life, and open new revenue streams.

4. What are the primary competitors to travoprost?
Latanoprost, bimatoprost, tafluprost, and emerging combination therapies.

5. How might regulatory changes affect travoprost sales?
Reimbursement policy adjustments and approval pathways for generics directly influence market penetration.

---

References

1. Grand View Research. (2022). Glaucoma Treatment Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/
2. Allergan Annual Report. (2022). Financial reporting for ophthalmic products. Retrieved from company filings.
3. U.S. Food and Drug Administration. (2022). ANDA approvals and patent listings. Retrieved from https://www.fda.gov/
4. European Medicines Agency. (2022). Regulatory updates on glaucoma medications. Retrieved from https://www.ema.europa.eu/
5. Santen Pharmaceutical. (2023). Product pipeline and market strategy reports. Retrieved from official site.